Jatenzo Cost in Maryland (2026): Prices, Insurance, and Savings Options

What Jatenzo Actually Costs at Maryland Pharmacies in 2026

The average cash-pay price for Jatenzo at Maryland retail pharmacies sits near $900 per month in 2026, matching Tolmar's wholesale acquisition cost. That figure applies to a standard 30-day supply of oral capsules at the most commonly prescribed maintenance dose. Prices vary by pharmacy location, with some Baltimore and D.C.-suburb chains pricing slightly above list and independent pharmacies occasionally discounting below it.

Why the Sticker Price Is High

Jatenzo is the first FDA-approved oral testosterone undecanoate capsule in the United States [1]. Its self-emulsifying lipid formulation bypasses the hepatotoxicity problems that kept earlier oral androgens off the U.S. Market for decades [2]. That patent-protected delivery technology means no AB-rated generic exists yet, and Tolmar holds pricing power typical of a branded specialty product.

How Maryland Stacks Up Regionally

Cash-pay prices in Maryland track closely with neighboring Virginia and Pennsylvania. The mid-Atlantic region lacks the deep discount pharmacy networks found in parts of Texas and Florida, so Maryland patients without insurance face the full $900 figure more often than patients in states with high-volume discount chains [3].

A 2020 pharmacoeconomic analysis estimated the annual cost of branded testosterone undecanoate at approximately $10,800, consistent with the $900 monthly price Maryland patients encounter today [4]. For comparison, injectable testosterone cypionate costs $30 to $90 per month at most Maryland pharmacies, making the oral convenience premium roughly 10-fold [5].

Insurance Coverage for Jatenzo in Maryland

Most Maryland insurers will cover Jatenzo if the prescriber documents confirmed male hypogonadism with two morning serum testosterone levels below 300 ng/dL, consistent with Endocrine Society 2018 guidelines [6]. Prior authorization is standard across virtually all plans.

Commercial Plans

CareFirst BlueCross BlueShield, the dominant commercial carrier in Maryland, lists Jatenzo on its specialty tier with step therapy requiring documentation that injectable testosterone was tried, contraindicated, or refused. UnitedHealthcare and Aetna plans sold on the Maryland Health Benefit Exchange follow similar PA criteria.

Approval typically requires:

• Two morning total testosterone values <300 ng/dL drawn on separate days
• A documented clinical diagnosis of hypogonadism (ICD-10 E29.1)
• A trial of or contraindication to injectable testosterone
• Prescriber attestation that the patient is male and aged 18 or older

Maryland Medicaid

Maryland Medicaid covers Jatenzo with prior authorization for adult males with confirmed hypogonadism [7]. The PA process routes through the state's preferred drug list, where Jatenzo sits in a non-preferred position. Prescribers must submit clinical documentation through the Maryland Department of Health's ePrescribing portal or fax. Approval turnaround averages 3 to 5 business days. Medicaid recipients pay no copay or a nominal copay of $1 to $3 depending on the managed care organization.

Medicare Part D

Traditional Medicare Part D plans generally classify Jatenzo as a Tier 4 or Tier 5 specialty drug. Out-of-pocket costs in the coverage gap can reach $200 to $400 per month before catastrophic coverage activates. The Inflation Reduction Act's $2,000 annual Part D cap, effective since 2025, limits total yearly exposure for Medicare beneficiaries filling Jatenzo [8].

The Tolmar Savings Card: How It Works in Maryland

Tolmar's manufacturer copay card is the single most effective tool for reducing out-of-pocket Jatenzo costs for commercially insured Maryland patients. Eligible patients can pay as little as $0 per fill, with Tolmar covering the difference up to a specified annual maximum.

Eligibility Rules

The card applies only to commercially insured patients. Federal healthcare program beneficiaries (Medicare, Medicaid, TRICARE, VA) are excluded by the Anti-Kickback Statute. Patients must have a valid Jatenzo prescription and fill at a participating pharmacy. Most Maryland chain pharmacies accept the card at point of sale.

Activation and Use

Patients register online through Tolmar's Jatenzo support hub, receive a digital card with BIN and PCN numbers, and present it at the pharmacy counter alongside their insurance card. The discount processes as a secondary payer after the primary insurer adjudicates the claim [9].

For uninsured patients, Tolmar also offers a separate patient assistance program with income-based eligibility, typically requiring household income below 400% of the federal poverty level.

Compounded Oral Testosterone Undecanoate in Maryland

Licensed 503A compounding pharmacies in Maryland can legally prepare oral testosterone undecanoate capsules for individual patients with valid prescriptions. This route bypasses the branded Jatenzo price entirely.

Legality and Regulation

Maryland's Board of Pharmacy permits 503A compounding under federal law (the Drug Quality and Security Act of 2013) as long as the pharmacy compounds pursuant to a patient-specific prescription and does not produce copies of commercially available drugs in "essentially a copy" quantities [10]. Because testosterone undecanoate is a bulk drug substance on the FDA's list for 503A use, Maryland 503A pharmacies can compound it.

Cost Comparison

Compounded oral testosterone undecanoate from a Maryland 503A pharmacy may cost significantly less than branded Jatenzo. Some compounding pharmacies advertise prices ranging from $50 to $200 per month depending on dose and formulation. The trade-off: compounded products lack the specific self-emulsifying drug delivery system (SEDDS) that Jatenzo uses to achieve reliable lymphatic absorption [11].

Bioavailability Considerations

The Swerdloff et al. Key trial (N=166) demonstrated that Jatenzo's SEDDS formulation achieved mean steady-state testosterone concentrations of 489 ng/dL across the approved dose range, with 87% of subjects reaching the eugonadal range of 300 to 1,100 ng/dL [11]. Compounded oral testosterone undecanoate without the SEDDS technology may produce different pharmacokinetic profiles. Clinicians prescribing compounded alternatives should monitor serum testosterone levels at 4 to 6 weeks and adjust doses accordingly [6].

Telehealth Access to Jatenzo in Maryland

Maryland permits telehealth prescribing of Jatenzo. The state's telehealth parity law mandates that insurers cover telehealth visits at the same rate as in-person visits, removing a potential barrier for patients in rural Western Maryland or the Eastern Shore who lack nearby endocrinologists [12].

How a Telehealth Jatenzo Prescription Works

A patient completes a video consultation with a licensed Maryland prescriber (MD, DO, NP, or PA with prescriptive authority). The prescriber reviews lab work confirming hypogonadism (two morning total testosterone levels <300 ng/dL) [6]. If clinical criteria are met, the prescriber sends an electronic prescription to the patient's preferred Maryland pharmacy, and the pharmacy processes the controlled substance fill under Maryland's PDMP requirements.

Controlled Substance Rules

Testosterone undecanoate is a Schedule III controlled substance under both federal and Maryland law. Maryland's Prescription Drug Monitoring Program (PDMP) requires the dispensing pharmacist to report each fill. Telehealth prescribers must comply with the Ryan Haight Act's requirement for at least one qualifying medical evaluation, which the DEA currently permits via real-time audio-visual telemedicine [13].

Cardiovascular Safety: What Maryland Prescribers Assess

The FDA mandated a cardiovascular outcomes trial for testosterone products following a 2015 label warning [14]. The TRAVERSE trial (N=5,246) found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.99; 95% CI 0.81 to 1.21) [14].

Blood Pressure Monitoring

Jatenzo's label carries a specific warning about dose-dependent increases in systolic blood pressure. In the key trial, mean systolic BP increased by 3 to 5 mmHg at higher doses [1]. The American Urological Association recommends blood pressure checks at each follow-up visit for patients on oral testosterone undecanoate [15]. Maryland prescribers typically schedule follow-up labs and vitals at 1 month, 3 months, and every 6 to 12 months thereafter.

Hematocrit and Polycythemia

Testosterone therapy raises hematocrit. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months, then annually, with dose reduction or therapeutic phlebotomy if hematocrit exceeds 54% [6]. In the Swerdloff trial, the incidence of hematocrit above 54% was 4.3% across all dose groups [11]. Maryland clinicians should counsel patients about symptoms of polycythemia, including headache, dizziness, and visual changes.

Strategies to Lower Your Jatenzo Cost in Maryland

No single approach works for every patient. The optimal cost-reduction strategy depends on insurance status, income, and willingness to use compounded alternatives.

For Commercially Insured Patients

1. Apply for the Tolmar savings card before the first fill
2. Ask the prescriber to submit PA with complete clinical documentation upfront to avoid delays
3. Use a specialty pharmacy that coordinates benefits and copay card stacking

For Medicaid Recipients

Maryland Medicaid's PA process requires prescriber-initiated documentation. Patients should confirm their managed care organization (e.g., Priority Partners, Jai Medical Systems, Maryland Physicians Care) has processed the PA before going to the pharmacy [7].

For Uninsured Patients

1. Apply for Tolmar's patient assistance program
2. Ask the prescriber about compounded oral testosterone undecanoate from a licensed Maryland 503A pharmacy
3. Compare prices across Maryland pharmacies using discount pricing tools

For Medicare Beneficiaries

The $2,000 annual Part D out-of-pocket cap limits exposure, but patients filling Jatenzo may hit that cap within 5 to 10 months depending on plan tier placement [8]. Switching to a Part D plan with lower specialty tier cost-sharing during open enrollment (October 15 to December 7) can reduce monthly costs.

How Jatenzo Compares to Other Testosterone Options in Maryland

Maryland patients choosing testosterone replacement have several formulations available beyond oral Jatenzo.

Injectable Testosterone Cypionate

The most commonly prescribed TRT formulation in the U.S., testosterone cypionate costs $30 to $90 per month for the generic version at Maryland pharmacies. It requires intramuscular or subcutaneous injection every 1 to 2 weeks. A meta-analysis of injectable testosterone formulations found comparable efficacy to oral routes in restoring eugonadal testosterone levels [16].

Topical Testosterone Gel (AndroGel, Vogelxo, Generics)

Topical gels cost $50 to $500 per month depending on brand versus generic and insurance tier. They require daily application and carry a secondary transfer risk to household contacts, which the FDA has addressed with a boxed warning [17].

Testosterone Pellets (Testopel)

Subcutaneous pellets implanted every 3 to 6 months cost $500 to $1,500 per procedure. They require an in-office procedure but eliminate daily or weekly dosing adherence. Maryland urologists and endocrinologists offer pellet insertion in most metropolitan areas.

Nasal Testosterone (Natesto)

Natesto, a nasal gel applied three times daily, costs approximately $500 to $700 per month. Its short pharmacokinetic profile may preserve spermatogenesis better than other exogenous testosterone routes, a relevant consideration for younger hypogonadal men who want to preserve fertility [18].

Who Should Consider Jatenzo Despite the Cost

Jatenzo fills a specific clinical niche. Patients who benefit most include those with needle phobia that prevents injectable TRT adherence, those with skin conditions or household contacts (children, pregnant partners) that make topical gels unsafe, and those who prefer the convenience of a twice-daily oral capsule taken with meals.

The FDA label specifies Jatenzo for adult males with conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) [1]. It is not indicated for age-related testosterone decline alone, and the Endocrine Society recommends against treating men whose only finding is low testosterone without symptoms [6].

Patients considering Jatenzo should bring recent lab results (two morning total testosterone values, CBC, lipid panel, PSA for men over 40) to their Maryland prescriber appointment. Starting dose is 237 mg taken orally twice daily with food, with dose adjustment based on serum testosterone measured 5 hours post-dose after at least 7 days of treatment [1].